Village Integrated Eye Workers Trial
Village Integrated Eye Workers Trial
批准号:
8737261
负责人:
THOMAS M LIETMAN
金额:
$59.35万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-30 至 2018-08-31
关键词:
AddressAfricaAnti-Bacterial AgentsAntibiotic ProphylaxisAntibioticsAntifungal AgentsAreaAsiaBhutanBlindnessCaliforniaCaringCensusesChloramphenicolCicatrixClinicClinicalClinical TrialsCohort StudiesCollaborationsCommunitiesCommunity HealthCommunity OutreachCorneaCorneal AbrasionCorneal DiseasesCorneal OpacityCorneal UlcerDeveloping CountriesDiagnosisEpidemiologyEthicsEyeEye diseasesHarvestHealthHealth PromotionHealth StatusHealth care facilityHealthcareHospitalsHourIncidenceIncidence StudyIndiaInfectionInterventionKeratitisLeadLeprosyMasksMeasuresMethodsMonitorMorbidity - disease rateMyanmarMycosesNepalOintmentsOnchocerciasisOutcomePatientsPersonsPoliciesPopulationPreventionPrevention programProphylactic treatmentRandomizedRandomized Clinical TrialsRandomized Controlled TrialsReadingRecording of previous eventsRelative (related person)ResearchResearch InfrastructureResolutionRuralRural CommunitySan FranciscoSeasonsServicesSurveysTrachomaTrainingTreatment EfficacyUlcerUnited StatesUniversitiesVillage Health WorkersVisionVisitVisualVisual impairmentWagesantimicrobialblindcostcost effectivecost effectivenesseffective interventioneffective therapyevidence baseimprovedmicrobialpopulation basedpreventprimary outcomeprogramsprospectiverandomized trialscale uptopical antibacterialtreatment programtrial comparinguptakevolunteer
中文摘要
描述(由申请人提供):本研究的目的是评估抗生素软膏预防对减少角膜溃疡和随后失明发生率的疗效。我们将随机接受旨在早期预防角膜磨损的强化健康促进措施的社区与接受标准护理(无主动干预)的社区进行比较。角膜溃疡是全球致盲的主要原因,一旦感染,就很难实质性地改善眼睛的视觉潜力。个体随机对照试验未能证明不同抗菌素或辅助治疗在临床结果上的巨大差异。前瞻性队列研究表明,抗生素预防
英文摘要
DESCRIPTION (provided by applicant): The objective of this study is to assess the efficacy of antibiotic ointment prophylaxis to reduce incidence of corneal ulceration and subsequent blindness. We compare communities randomized to receive an intensive health promotion effort aimed at early prophylaxis for corneal abrasion to communities receiving standard-of care (no active intervention). Corneal ulceration is a leading cause of blindness globally, and once infection is present it is difficult to substantially improve visual potential of the eye. Individully randomized controlled trials have been unsuccessful at demonstrating large differences in clinical outcomes with different antimicrobial or adjunctive therapies. Prospective cohort studies have suggested that antibiotic prophylaxis
Is effective at reducing corneal ulceration, but a community randomized clinical trial is necessary to provide definitive evidence of the efficacy of interventions with antibiotic prophylaxis at the community level. We expect that this study will provide an evidence base for such an intervention through the following specific aims: 1) to determine if antibiotic prophylaxis
after corneal abrasion reduces the incidence of corneal ulceration in a community randomized trial. 2) To assess the costs and cost-effectiveness of a preventative intervention for microbial keratitis. 3) To determine the incidence of corneal ulceration and abrasion in this district of Taml Nadu, India. No community-randomized trial has ever been performed for microbial keratitis. These trials are difficult to conduct, because of infrastructure and logistical requirements as wel as ethical considerations. We address this by building on our collaborations between the University of California, San Francisco and the Aravind Eye Hospital in Madurai, India. Aravind has an existing infrastructure of community outreach and vision centers that will allow for this study to be completed at a large scale. Patients in control communities will receive treatment should they seek it, as it would be unethical not to provide treatment, but these communities will not receive active health promotion activities. If proven to be effective, this study will provide definitive evidence on a cost-effective, scalable intervention that could substantially reduce the burden of blindness particularly in rural communities in the developing world.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Azithromycin Reduction to Reach Elimination of Trachoma
-
批准号:10439385
-
项目类别:
-
资助金额:$5.08万
-
财政年份:2020
-
负责人:THOMAS M LIETMAN
-
依托单位:
Azithromycin Reduction to Reach Elimination of Trachoma
-
批准号:10616840
-
项目类别:
-
资助金额:$7.34万
-
财政年份:2020
-
负责人:THOMAS M LIETMAN
-
依托单位:
Azithromycin Reduction to Reach Elimination of Trachoma
-
批准号:10397057
-
项目类别:
-
资助金额:$76.63万
-
财政年份:2020
-
负责人:THOMAS M LIETMAN
-
依托单位:
UCSF-Proctor Clinician Vision Scholars K12 Program
-
批准号:10610924
-
项目类别:
-
资助金额:$53.14万
-
财政年份:2020
-
负责人:THOMAS M LIETMAN
-
依托单位:
UCSF-Proctor Clinician Vision Scholars K12 Program
-
批准号:10409646
-
项目类别:
-
资助金额:$53.14万
-
财政年份:2020
-
负责人:THOMAS M LIETMAN
-
依托单位:
Azithromycin Reduction to Reach Elimination of Trachoma
-
批准号:10907941
-
项目类别:
-
资助金额:$2.6万
-
财政年份:2020
-
负责人:THOMAS M LIETMAN
-
依托单位:
Azithromycin Reduction to Reach Elimination of Trachoma
-
批准号:10618166
-
项目类别:
-
资助金额:$79.31万
-
财政年份:2020
-
负责人:THOMAS M LIETMAN
-
依托单位:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
-
批准号:10397960
-
项目类别:
-
资助金额:$1.3万
-
财政年份:2019
-
负责人:THOMAS M LIETMAN
-
依托单位:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
-
批准号:10457913
-
项目类别:
-
资助金额:$79.62万
-
财政年份:2019
-
负责人:THOMAS M LIETMAN
-
依托单位:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
-
批准号:10222699
-
项目类别:
-
资助金额:$86.37万
-
财政年份:2019
-
负责人:THOMAS M LIETMAN
-
依托单位:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
-
批准号:10666415
-
项目类别:
-
资助金额:$74.59万
-
财政年份:2019
-
负责人:THOMAS M LIETMAN
-
依托单位:
Steroids and Cross-linking for Ulcer Treatment (SCUT II)
-
批准号:10167111
-
项目类别:
-
资助金额:$8.71万
-
财政年份:2019
-
负责人:THOMAS M LIETMAN
-
依托单位:
Kebele Elimination of Trachoma for Ocular Health
-
批准号:9752569
-
项目类别:
-
资助金额:$60.55万
-
财政年份:2017
-
负责人:THOMAS M LIETMAN
-
依托单位:
Kebele Elimination of Trachoma for Ocular Health
-
批准号:10441068
-
项目类别:
-
资助金额:$84.29万
-
财政年份:2017
-
负责人:THOMAS M LIETMAN
-
依托单位:
Kebele Elimination of Trachoma for Ocular Health
-
批准号:9965928
-
项目类别:
-
资助金额:$62.62万
-
财政年份:2017
-
负责人:THOMAS M LIETMAN
-
依托单位:
Forecasting Trachoma Control
-
批准号:9107191
-
项目类别:
-
资助金额:$39.94万
-
财政年份:2016
-
负责人:THOMAS M LIETMAN
-
依托单位:
Digital Detection of Infectious Eye Epidemics
-
批准号:9030980
-
项目类别:
-
资助金额:$39.42万
-
财政年份:2016
-
负责人:THOMAS M LIETMAN
-
依托单位:
Digital Detection of Infectious Eye Epidemics
-
批准号:9207459
-
项目类别:
-
资助金额:$37.6万
-
财政年份:2016
-
负责人:THOMAS M LIETMAN
-
依托单位:
Forecasting Trachoma Control
-
批准号:10587368
-
项目类别:
-
资助金额:$40.38万
-
财政年份:2016
-
负责人:THOMAS M LIETMAN
-
依托单位:
Forecasting Trachoma Control
-
批准号:9267470
-
项目类别:
-
资助金额:$39.94万
-
财政年份:2016
-
负责人:THOMAS M LIETMAN
-
依托单位:
海外基金